CoV2-OGEN1 / Syneos Health, US Specialty Formulations - LARVOL DELTA

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Syneos Health | Active, not recruiting ➔ Completed | Trial primary completion date: Dec 2021 ➔ Nov 2022

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects (clinicaltrials.gov) - P1; N=45; Active, not recruiting; Sponsor: Syneos Health; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects (clinicaltrials.gov) - P1; N=45; Recruiting; Sponsor: Syneos Health; Not yet recruiting ➔ Recruiting; Trial primary completion date: Jun 2021 ➔ Oct 2021

Clinical • Enrollment open • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects (clinicaltrials.gov) - P1; N=45; Not yet recruiting; Sponsor: Syneos Health; Trial completion date: Feb 2022 ➔ Sep 2022

Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects (clinicaltrials.gov) - P1; N=45; Not yet recruiting; Sponsor: Syneos Health

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases